Immucell Stock Performance
| ICCC Stock | USD 5.44 0.04 0.74% |
On a scale of 0 to 100, ImmuCell holds a performance score of 14. The company retains a Market Volatility (i.e., Beta) of -0.14, which attests to not very significant fluctuations relative to the market. As returns on the market increase, returns on owning ImmuCell are expected to decrease at a much lower rate. During the bear market, ImmuCell is likely to outperform the market. Please check ImmuCell's jensen alpha, maximum drawdown, semi variance, as well as the relationship between the sortino ratio and potential upside , to make a quick decision on whether ImmuCell's current trending patterns will revert.
Risk-Adjusted Performance
14 of 100
Weak | Strong |
Good
Compared to the overall equity markets, risk-adjusted returns on investments in ImmuCell are ranked lower than 14 (%) of all global equities and portfolios over the last 90 days. In spite of rather fragile fundamental indicators, ImmuCell exhibited solid returns over the last few months and may actually be approaching a breakup point. ...more
| Begin Period Cash Flow | 5.8 M |
ImmuCell |
ImmuCell Relative Risk vs. Return Landscape
If you would invest 359.00 in ImmuCell on November 2, 2024 and sell it today you would earn a total of 185.00 from holding ImmuCell or generate 51.53% return on investment over 90 days. ImmuCell is currently generating 0.7875% in daily expected returns and assumes 4.3491% risk (volatility on return distribution) over the 90 days horizon. In different words, 38% of stocks are less volatile than ImmuCell, and 85% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
ImmuCell Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for ImmuCell's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as ImmuCell, and traders can use it to determine the average amount a ImmuCell's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.1811
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ICCC | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 4.35 actual daily | 38 62% of assets are more volatile |
Expected Return
| 0.79 actual daily | 15 85% of assets have higher returns |
Risk-Adjusted Return
| 0.18 actual daily | 14 86% of assets perform better |
Based on monthly moving average ImmuCell is performing at about 14% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of ImmuCell by adding it to a well-diversified portfolio.
ImmuCell Fundamentals Growth
ImmuCell Stock prices reflect investors' perceptions of the future prospects and financial health of ImmuCell, and ImmuCell fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on ImmuCell Stock performance.
| Return On Equity | -0.16 | ||||
| Return On Asset | -0.0487 | ||||
| Profit Margin | (0.17) % | ||||
| Operating Margin | (0.25) % | ||||
| Current Valuation | 59.85 M | ||||
| Shares Outstanding | 8.91 M | ||||
| Price To Earning | 195.00 X | ||||
| Price To Book | 1.82 X | ||||
| Price To Sales | 2.09 X | ||||
| Revenue | 17.47 M | ||||
| EBITDA | (2.5 M) | ||||
| Cash And Equivalents | 11.04 M | ||||
| Cash Per Share | 1.43 X | ||||
| Total Debt | 16.69 M | ||||
| Debt To Equity | 0.36 % | ||||
| Book Value Per Share | 3.23 X | ||||
| Cash Flow From Operations | (4.67 M) | ||||
| Earnings Per Share | (0.49) X | ||||
| Total Asset | 43.81 M | ||||
| Retained Earnings | (12.01 M) | ||||
| Current Asset | 4.49 M | ||||
| Current Liabilities | 258.78 K | ||||
About ImmuCell Performance
By analyzing ImmuCell's fundamental ratios, stakeholders can gain valuable insights into ImmuCell's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if ImmuCell has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if ImmuCell has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
ImmuCell Corporation, an animal health company, develops, manufactures, and markets products that enhance the health and productivity of dairy and beef cattle in the United States and internationally. ImmuCell Corporation was incorporated in 1982 and is headquartered in Portland, Maine. Immucell operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 64 people.Things to note about ImmuCell performance evaluation
Checking the ongoing alerts about ImmuCell for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for ImmuCell help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| ImmuCell appears to be risky and price may revert if volatility continues | |
| The company reported the previous year's revenue of 17.47 M. Net Loss for the year was (5.77 M) with profit before overhead, payroll, taxes, and interest of 7.65 B. | |
| ImmuCell currently holds about 11.04 M in cash with (4.67 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.43. | |
| Roughly 40.0% of the company shares are held by company insiders |
- Analyzing ImmuCell's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether ImmuCell's stock is overvalued or undervalued compared to its peers.
- Examining ImmuCell's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating ImmuCell's management team can have a significant impact on its success or failure. Reviewing the track record and experience of ImmuCell's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of ImmuCell's stock. These opinions can provide insight into ImmuCell's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for ImmuCell Stock analysis
When running ImmuCell's price analysis, check to measure ImmuCell's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ImmuCell is operating at the current time. Most of ImmuCell's value examination focuses on studying past and present price action to predict the probability of ImmuCell's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ImmuCell's price. Additionally, you may evaluate how the addition of ImmuCell to your portfolios can decrease your overall portfolio volatility.
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation |